Provectus cites success with anti-cancer agent PV-10

By Elaine Rigoli

Tampa, Fla., Sept. 14 - Provectus Pharmaceuticals, Inc. said the company's leading anticancer agent, PV-10, completely ablated a cluster of metastatic melanoma tumors afflicting a clinical trial participant.

The Knoxville, Tenn.-based biopharmaceutical company said treatment of one of the tumors with PV-10 led to complete eradication of all four tumors that had repeatedly resisted treatment with surgery, chemotherapy and radiation therapy.

Without this treatment, this man most likely would have survived for only a few months, according to the company.

The 86-year-old man is part of a 20-subject phase 1 study of the safety and efficacy of PV-10, an injectable formulation of Rose Bengal, also known as Provecta, for the ablation of metastatic melanoma, an aggressive and often fatal form of skin cancer.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.